Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy

Journal of General Virology

Volumn 94, Issue PART 5, 2013, Pages 1121-1126

  Sumner, Rebecca P ^a   Ren, Hongwei ^a   Smith, Geoffrey L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATORY PROTEIN C6; PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE; HUMORAL IMMUNITY; IMMUNOGENICITY; INOCULATION; NONHUMAN; PRIORITY JOURNAL; SPLEEN; VACCINATION; VACCINIA VIRUS; VIRULENCE; VIRUS ATTENUATION; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS STRAIN;

EID: 84876214935     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.049700-0     Document Type: Article

References (43)

1. Assarsson, E., Greenbaum, J. A., Sundström, M., Schaffer, L., Hammond, J. A., Pasquetto, V., Oseroff, C., Hendrickson, R. C., Lefkowitz, E. J. & other authors (2008). Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105, 2140-2145
2. Bennink, J. R., Yewdell, J. W., Smith, G. L., Moller, C. & Moss, B. (1984). Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311, 578-579
3. Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79, 1159-1167
4. Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006). Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87, 29-38
5. Cottingham, M. G., Andersen, R. F., Spencer, A. J., Saurya, S., Furze, J., Hill, A. V. & Gilbert, S. C. (2008). Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 3, e1638
6. Delaloye, J., Roger, T., Steiner-Tardivel, Q. G., Le Roy, D., Knaup Reymond, M., Akira, S., Petrilli, V., Gomez, C. E., Perdiguero, B. & other authors (2009). Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5, e1000480
7. Fahy, A. S., Clark, R. H., Glyde, E. F. & Smith, G. L. (2008). Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol 89, 2377-2387
8. Falivene, J., Del Médico Zajac, M. P., Pascutti, M. F., Rodríguez, A. M., Maeto, C., Perdiguero, B., Gómez, C. E., Esteban, M., Calamante, G. & Gherardi, M. M. (2012). Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS ONE 7, e32220
9. Fenner, F., Anderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and its Eradication. Geneva: World Health Organisation.
10. Fujita, F., Taniguchi, Y., Kato, T., Narita, Y., Furuya, A., Ogawa, T., Sakurai, H., Joh, T., Itoh, M. & other authors (2003). Identification of NAP1, a regulatory subunit of IkB kinase-related kinases that potentiates NF-kB signaling. Mol Cell Biol 23, 7780-7793
11. García-Arriaza, J., Nájera, J. L., Gómez, C. E., Tewabe, N., Sorzano, C. O., Calandra, T., Roger, T. & Esteban, M. (2011). A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE 6, e24244
12. Gómez, C. E., Nájera, J. L., Krupa, M. & Esteban, M. (2008). The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8, 97-120
13. Gómez, C. E., Perdiguero, B., Nájera, J. L., Sorzano, C. O., Jiménez, V., González-Sanz, R. & Esteban, M. (2012). Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86, 5026-5038
14. González, J. M. & Esteban, M. (2010). A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J 7, 59
15. Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A., Whalen, D. M., Abrescia, N. G., Alderton, D., Owens, R. J., Stuart, D. I. & other authors (2008). Vaccinia virus proteins A52 and B14 share a Bcl-2- like fold but have evolved to inhibit NF-kB rather than apoptosis. PLoS Pathog 4, e1000128
16. Gubser, C., Hué, S., Kellam, P. & Smith, G. L. (2004). Poxvirus genomes: a phylogenetic analysis. J Gen Virol 85, 105-117
17. Lane, J. M., Ruben, F. L., Neff, J. M. & Millar, J. D. (1969). Complications of smallpox vaccination, 1968. N Engl J Med 281, 1201-1208
18. Law, M., Pü tz, M. M. & Smith, G. L. (2005). An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol 86, 991-1000
19. Lefkowitz, E. J., Wang, C. & Upton, C. (2006). Poxviruses: past, present and future. Virus Res 117, 105-118
20. Mackett, M., Smith, G. L. & Moss, B. (1982). Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79, 7415-7419
21. Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031-1038
22. Moore, J. B. & Smith, G. L. (1992). Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J 11, 1973-1980
23. Moss, B. (2007). Poxviridae: the viruses and their replication. In Fields Virology, 5th edn, pp. 2905-2946. Edited by D. M. Knipe. Philadelphia: Lippincott Williams & Wilkins.
24. Moss, B. (2011). Smallpox vaccines: targets of protective immunity. Immunol Rev 239, 8-26
25. Panicali, D. & Paoletti, E. (1982). Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 79, 4927-4931
26. Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. (1983). Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A 80, 5364-5368
27. Pomerantz, J. L. & Baltimore, D. (1999). NF-kB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKKrelated kinase. EMBO J 18, 6694-6704
28. Pütz, M. M., Midgley, C. M., Law, M. & Smith, G. L. (2006). Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12, 1310-1315
29. Reading, P. C., Moore, J. B. & Smith, G. L. (2003a). Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197, 1269-1278
30. Reading, P. C., Symons, J. A. & Smith, G. L. (2003b). A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol 170, 1435-1442
31. Rehm, K. E. & Roper, R. L. (2011). Deletion of the A35 gene from modified vaccinia virus Ankara increases immunogenicity and isotype switching. Vaccine 29, 3276-3283
32. Ryzhakov, G. & Randow, F. (2007). SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J 26, 3180-3190
33. Schröder, M., Baran, M. & Bowie, A. G. (2008). Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKe-mediated IRF activation. EMBO J 27, 2147-2157
34. Smith, G. L., Mackett, M. & Moss, B. (1983a). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302, 490-495
35. Smith, G. L., Murphy, B. R. & Moss, B. (1983b). Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A 80, 7155-7159
36. Staib, C., Kisling, S., Erfle, V. & Sutter, G. (2005). Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 86, 1997-2006
37. Tscharke, D. C. & Smith, G. L. (1999). A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80, 2751-2755
38. Tscharke, D. C., Reading, P. C. & Smith, G. L. (2002). Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 83, 1977-1986
39. Tscharke, D. C., Karupiah, G., Zhou, J., Palmore, T., Irvine, K. R., Haeryfar, S. M., Williams, S., Sidney, J., Sette, A. & other authors (2005). Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J ExpMed 201, 95-104
40. Tscharke, D. C., Woo, W. P., Sakala, I. G., Sidney, J., Sette, A., Moss, D. J., Bennink, J. R., Karupiah, G. & Yewdell, J. W. (2006). Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80, 6318-6323
41. Unterholzner, L., Sumner, R. P., Baran, M., Ren, H., Mansur, D. S., Bourke, N. M., Randow, F., Smith, G. L. & Bowie, A. G. (2011). Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 7, e1002247
42. Upton, C., Slack, S., Hunter, A. L., Ehlers, A. & Roper, R. L. (2003). Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J Virol 77, 7590-7600
43. Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. (1990). Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71, 2761-2767.